Pancreatic cancer
Immunotherapy can be used as a first-line cancer treatment for patients with pancreatic cancer, and the FDA has approved one immunotherapy treatment for patients with pancreatic cancer, while additional research is ongoing. The only immunotherapy treatment for pancreatic cancer is as follows:
Immunomodulating agents:
The drug Pembrolizumab
Pembrolizumab is one of the checkpoint inhibitors that destroys cancer cells via the PD-1/PD-L pathway and can be used to treat advanced pancreatic cancer. Pembrolizumab is an excellent treatment option for advanced pancreatic cancer patients with elevated microsatellite instability (MSI-H), high tumor mutational burden (TMB-H), and deficient DNA mismatch repair (dMMR).
